The Gα13 pathway is affected by inactivating mutations in approximately 20% of GCB-DLBCL, including lesions in GNA13, S1PR2, ARHGEF1 and P2RY8 (2, 3, 5, 14, 49). The gene discussed is S1PR2; the disease is diffuse large B-cell lymphoma.